The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
PD1 signal transduction pathways in T cells
Open accessAbstract
// Hugo Arasanz 1, * , Maria Gato-Cañas 1, * , Miren Zuazo 1, * , Maria Ibañez-Vea 1, * , Karine Breckpot 3 , Grazyna Kochan 1 and David Escors 1, 2 1 Immunomodulation Group, Navarrabiomed-Biomedical Research Centre, IdISNA, Pamplona, Spain 2 Rayne Institute, Division of Infection and Immunity, University College London, London, United Kindom 3 Laboratory of Molecular and Cellular Therapy Department of Biomedical Sciences, Vrije Universiteit Brussel, Brussels, Belgium * These authors have contributed equally to this work Correspondence to: David Escors, email: descorsm@navarra.es Grazyna Kochan, email: grazyna.kochan@navarra.es Keywords: PD-L1, PDL1, PD1, B7-H1, cancer Received: February 28, 2017 Accepted: March 24, 2017 Published: April 19, 2017 ABSTRACT The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block PD-L1/PD1 interactions between cancer cells and T cells are demonstrating high efficacies and low toxicities. Despite all the recent advances, very little is yet known on the molecular intracellular signaling pathways regulated by either PD-L1 or PD1. Here we review the current knowledge on PD1-dependent intracellular signaling pathways, and the consequences of disrupting PD1 signal transduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“The nature of these T cells has not been elucidated yet, but these reactivated T cells may be behind of some of the autoreactive adverse events associated to treatments with immune checkpoint inhibitors [52, 53].”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“These T cells are antigen-experienced but they have been inactivated by the tumor [47].”
BackgroundNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · cited 1×
“In the direct pathway of TCR inhibition, engaged PD1 terminates ZAP70 and PI3K phosphorylation by recruiting SHP1 and SHP2 phosphatases to its tyrosine phosphorylated ITIM and ITSM motifs [14, 15] (Figure 2A).”
BackgroundThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Simpson, T. R., Li, F., Montalvo-Ortiz, W., Sepulveda, M. A., Bergerhoff, K., Arce, F., Roddie, C., Henry, J. Y., Yagita, H., Wolchok, J. D., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130579 · Cited by 1,472
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246
CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-xL
Boise, L. H., Minn, A. J., Noel, P. J., June, C. H., Accavitti, M. A., Lindsten, T., & Thompson, C. B. (1995) · Immunity · doi:10.1016/1074-7613(95)90161-2 · Cited by 1,210
Patsoukis, N., Bardhan, K., Chatterjee, P., Sari, D., Liu, B., Bell, L. N., Karoly, E. D., Freeman, G. J., Petkova, V., Seth, P., et al. (2015) · Nature Communications · doi:10.1038/ncomms7692 · Cited by 1,202
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161
ZAP-70: A 70 kd protein-tyrosine kinase that associates with the TCR ζ chain
Chan, A. C., Iwashima, M., Turck, C. W., & Weiss, A. (1992) · Cell · doi:10.1016/0092-8674(92)90598-7 · Cited by 1,041
Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Kamphorst, A. O., Wieland, A., Nasti, T., Yang, S., Zhang, R., Barber, D. L., Konieczny, B. T., Daugherty, C. Z., Koenig, L., Yu, K., et al. (2017) · Science · doi:10.1126/science.aaf0683 · Cited by 1,015 · cited 1×
“The reactivation of this pool of antigen-experienced T cells seems to be the driver of the efficacy of PD-L1/PD1 blockade in human therapy [49].”
BackgroundSheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Hodi, F. S., Hwu, W.-J., Kefford, R., Weber, J. S., Daud, A., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 734
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Molecular Basis of T Cell Inactivation by CTLA-4
Lee, K.-M., Chuang, E., Griffin, M., Khattri, R., Hong, D. K., Zhang, W., Straus, D., Samelson, L. E., Thompson, C. B., & Bluestone, J. A. (1998) · Science · doi:10.1126/science.282.5397.2263 · Cited by 684
Negative regulation of lymphocyte activation and autoimmunity by the molecular adaptor Cbl-b
Bachmaier, K., Krawczyk, C., Kozieradzki, I., Kong, Y.-Y., Sasaki, T., Oliveira-dos-Santos, A., Mariathasan, S., Bouchard, D., Wakeham, A., Itie, A., et al. (2000) · Nature · doi:10.1038/35003228 · Cited by 666
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639
Latchman, Y. E., Liang, S. C., Wu, Y., Chernova, T., Sobel, R. A., Klemm, M., Kuchroo, V. K., Freeman, G. J., & Sharpe, A. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307252101 · Cited by 636
Alterations in Signal Transduction Molecules in T Lymphocytes from Tumor-Bearing Mice
Mizoguchi, H., O'Shea, J. J., Longo, D. L., Loeffler, C. M., McVicar, D. W., & Ochoa, A. C. (1992) · Science · doi:10.1126/science.1465616 · Cited by 632
Immunostimulatory monoclonal antibodies for cancer therapy
Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D. M., & Chen, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2051 · Cited by 627
Cbl-b regulates the CD28 dependence of T-cell activation
Chiang, Y. J., Kole, H. K., Brown, K., Naramura, M., Fukuhara, S., Hu, R.-J., Jang, I. K., Gutkind, J. S., Shevach, E., & Gu, H. (2000) · Nature · doi:10.1038/35003235 · Cited by 621
Patsoukis, N., Brown, J., Petkova, V., Liu, F., Li, L., & Boussiotis, V. A. (2012) · Science Signaling · doi:10.1126/scisignal.2002796 · Cited by 529
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Daud, A. I., Loo, K., Pauli, M. L., Sanchez-Rodriguez, R., Sandoval, P. M., Taravati, K., Tsai, K., Nosrati, A., Nardo, L., Alvarado, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87324 · Cited by 525
Signal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells
Curtsinger, J. M., Lins, D. C., & Mescher, M. F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021910 · Cited by 509
Rathmell, J. C., Heiden, M. G. V., Harris, M. H., Frauwirth, K. A., & Thompson, C. B. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00066-6 · Cited by 467
PD-1 Blockade Expands Intratumoral Memory T Cells
Ribas, A., Shin, D. S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., Seja, E., Kivork, C., Siebert, J., Kaplan-Lefko, P., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0210 · Cited by 405 · cited 1×
“Reactivation of these experienced memory T cells might be the cause of the efficacy of PD-L1/ PD1 blockade in patients with PD-L1-positive tumors [48].”
BackgroundDirect Regulation of ZAP-70 by SHP-1 in T Cell Antigen Receptor Signaling
Plas, D. R., Johnson, R., Pingel, J. T., Matthews, R. J., Dalton, M., Roy, G., Chan, A. C., & Thomas, M. L. (1996) · Science · doi:10.1126/science.272.5265.1173 · Cited by 390
c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation
Naramura, M., Jang, I.-K., Kole, H., Huang, F., Haines, D., & Gu, H. (2002) · Nature Immunology · doi:10.1038/ni855 · Cited by 390
Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma.
Finke, J. H., Zea, A. H., Stanley, J., Longo, D., Mizoguchi, H., Tubbs, R. R., Wiltrout, R. H., O’Shea, J. J., Kudoh, S., & Klein, E. A. (1993) · PubMed · Cited by 379
T Cell Replicative Senescence in Human Aging
P. Chou, J., & B. Effros, R. (2013) · Current Pharmaceutical Design · doi:10.2174/138161213805219711 · Cited by 323
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases
Salvador, J. M., Mittelstadt, P. R., Guszczynski, T., Copeland, T. D., Yamaguchi, H., Appella, E., Fornace, A. J., & Ashwell, J. D. (2005) · Nature Immunology · doi:10.1038/ni1177 · Cited by 306
Curtsinger, J. M., Johnson, C. M., & Mescher, M. F. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.10.5165 · Cited by 287
Proteolysis-independent regulation of PI3K by Cbl-b–mediated ubiquitination in T cells
Fang, D., & Liu, Y.-C. (2001) · Nature Immunology · doi:10.1038/ni0901-870 · Cited by 276
PD‐L1 co‐stimulation contributes to ligand‐induced T cell receptor down‐modulation on CD8 + T cells
Karwacz, K., Bricogne, C., MacDonald, D., Arce, F., Bennett, C. L., Collins, M., & Escors, D. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100165 · Cited by 265
Self-citationT‐cell tolerance or function is determined by combinatorial costimulatory signals
Nurieva, R., Thomas, S., Nguyen, T., Martin‐Orozco, N., Wang, Y., Kaja, M., Yu, X., & Dong, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601146 · Cited by 245
Shlapatska, L. M., Mikhalap, S. V., Berdova, A. G., Zelensky, O. M., Yun, T. J., Nichols, K. E., Clark, E. A., & Sidorenko, S. P. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5480 · Cited by 217
Patsoukis, N., Li, L., Sari, D., Petkova, V., & Boussiotis, V. A. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00319-13 · Cited by 187
Sieh, M., Batzer, A., Schlessinger, J., & Weiss, A. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4435-4442.1994 · Cited by 175
Huang, H., Jeon, M.-S., Liao, L., Yang, C., Elly, C., Yates, J. R., & Liu, Y.-C. (2010) · Immunity · doi:10.1016/j.immuni.2010.07.002 · Cited by 174
Moreno, B. H., Zaretsky, J. M., García-Díaz, Á., Tsoi, J., Parisi, G., Robert, L., Meeth, K. M., Ndoye, A., Bosenberg, M., Weeraratna, A. T., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0060 · Cited by 160
PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A
Patsoukis, N., Sari, D., & Boussiotis, V. A. (2012) · Cell Cycle · doi:10.4161/cc.22135 · Cited by 143
Round, J. L., Humphries, L. A., Tomassian, T., Mittelstadt, P. R., Zhang, M., & Miceli, M. C. (2006) · Nature Immunology · doi:10.1038/ni1422 · Cited by 126
Karunarathne, D. S., Horne‐Debets, J. M., Huang, J. X., Faleiro, R. J., Leow, C. Y., Amante, F. H., Watkins, T. S., Miles, J. J., Dwyer, P., Stacey, K. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.017 · Cited by 104
Sieh, M., Batzer, A., Schlessinger, J., & Weiss, A. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.7.4435 · Cited by 103
Pen, J. J., Keersmaecker, B. D., Heirman, C., Corthals, J., Liechtenstein, T., Escors, D., Thielemans, K., & Breckpot, K. (2014) · Gene Therapy · doi:10.1038/gt.2013.80 · Cited by 83
Self-citationDufait, I., Schwarze, J. K., Liechtenstein, T., Leonard, W., Jiang, H., Escors, D., Ridder, M. D., & Breckpot, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3682 · Cited by 81
Self-citationLiechtenstein, T., Pérez‐Janices, N., Gato, M., Caliendo, F., Kochan, G. T., Blanco‐Luquin, I., der Jeught, K. V., Vargas, F. A., Guerrero‐Setas, D., Fernández‐Irigoyen, J., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2279 · Cited by 71
Self-citationA core of kinase-regulated interactomes defines the neoplastic MDSC lineage
Gato, M., de Morentin, X. M., Blanco‐Luquin, I., Fernández‐Irigoyen, J., Zudaire, I., Liechtenstein, T., Arasanz, H., Lozano, T., Casares, N., Chaikuad, A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4746 · Cited by 60
Self-citationShamim, M. H., Nanjappa, S. G., Singh, A., Plisch, E. H., LeBlanc, S. E., Walent, J. H., Svaren, J. P., Seroogy, C. M., & Suresh, M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7233 · Cited by 49
Liechtenstein, T., Pérez‐Janices, N., Blanco‐Luquin, I., Goyvaerts, C., Schwarze, J. K., Dufait, I., Lanna, A., Ridder, M. D., Guerrero‐Setas, D., Breckpot, K., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.945378 · Cited by 48
Self-citationCombination Immunotherapy with 4-1BBL and CTLA-4 Blockade for the Treatment of Prostate Cancer
Youlin, K., Li, Z., Xiaodong, W., Xiuheng, L., & Hengchen, Z. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/439235 · Cited by 36
Ney, J. T., Schmidt, T., Kurts, C., Zhou, Q., Eckert, D., Felsher, D. W., Schorle, H., Knolle, P. A., Tüting, T., Barchet, W., et al. (2008) · Hepatology · doi:10.1002/hep.22652 · Cited by 19
Novel Immunotherapies for the Treatment of Melanoma
Gato, M., Arasanz, H., Blanco‐Luquin, I., Glaría, E., Arteta-Sanchez, V., Kochan, G. T., & Escors, D. (2016) · Immunotherapy · doi:10.2217/imt-2015-0024 · Cited by 10
Self-citation
Cited by
Cytotoxic CD8+ T cells in cancer and cancer immunotherapy
Raskov, H., Orhan, A., Christensen, J. P., & Gögenur, I. (2021) · British Journal of Cancer · doi:10.1038/s41416-020-01048-4 · Cited by 1,687
Saeidi, A., Zandi, K., Cheok, Y. Y., Saeidi, H., Wong, W. F., Lee, C. Y. Q., Cheong, H. C., Yong, Y. K., Larsson, M., & Shankar, E. M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02569 · Cited by 350
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer
Atsaves, V., Leventaki, V., Rassidakis, G. Z., & Claret, F. X. (2019) · Cancers · doi:10.3390/cancers11071037 · Cited by 293
The intracellular signalosome of PD-L1 in cancer cells
Escors, D., Gato-Cañas, M., Zuazo, M., Arasanz, H., García-Granda, M. J., Vera, R., & Kochan, G. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-018-0022-9 · Cited by 292
Self-citationSmall molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Metadata
- Authors
- Arasanz, H., Gato-Cañas, M., Zuazo, M., Ibañez-Vea, M., Breckpot, K., Kochan, G., & Escors, D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2017-04-19
- Volume
- 8
- Issue
- 31
- Pages
- 51936-51945
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2606939149
- Cited by
- 270
- References
- 65
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.